The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | ETCTN P10500: a Phase I/expansion study of tazemetostat plus belinostat for R/R NHL
Jennifer Amengual, MD, Columbia University Irving Medical Center, New York City, NY, shares some insights into the Phase I/expansion ETCTN P10500 trial (NCT05627245) investigating the safety of tazemetostat plus belinostat in patients with relapsed/refractory (R/R ) non-Hodgkin lymphomas (NHLs), which includes an expansion cohort of patients with R/R germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL). Dr Amengual explains the biological reasoning for this treatment combination and discusses the correlative studies within this trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
